Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a $175 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAZZ:
- ALX Oncology announces results from Phase 1b/2 trial
- Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines
- Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio
- Roche announces FDA approval of label expansion into biliary tract cancer
- FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
